Antiangiogenic Agents Are Effective Inhibitors of Endometriosis

kevin g osteen,brian d m tom,s k smith,kaylon l brunertran,m louise hull,clement l k chan,d stephen carnockjones,taiping d fan

DOI: https://doi.org/10.1097/01.ogx.0000094484.02537.77

2003-01-01

Obstetrical & Gynecological Survey

Abstract:In endometriosis, the endometrial lining of the uterus that is shed during menstruation becomes established as explants in the peritoneum, ovaries, and other sites. They develop a rich blood supply that promotes and sustains their growth. This study examined the hypothesis that agents inhibiting angiogenesis would prevent the growth of these explants. An attempt was made to specifically counter vascular endothelial cell growth factor A (VEGF-A), which is found at elevated levels in the peritoneal fluid of women with endometriosis. The blood vessels supplying human endometriotic lesions were found on immunohistochemical study to be mainly free of pericytes, as are vessels sensitive to angiogenic antagonists, and were in fact responsive to VEGF-A. In samples from 8 women, the proportion of such vessels was significantly higher in ectopic than in eutopic endometrium. When human endometrial tissue was implanted into nude mice, both soluble truncated receptor (flt-1) and a purified antibody to human VECF-A significantly inhibited growth of the implants. Pericyte-free vessels, which supplied the endometrial explants, were disrupted in lesions from mice treated with soluble fit-1. The findings were validated by studies in a rat sponge model, in which the increase in blood flow stimulated by growth factor was nearly completely eliminated by low-dose soluble FLT-1. These findings suggest that anti-VEGF-A agents might be able to disrupt the vascular supply of endometriotic lesions. The investigators believe that such antiangiogenic agents are likely to be effective in the clinical treatment of endometriosis.